• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Gen Intern Med . Evaluation of Five Commercial SARS-CoV-2 Antigen Tests in a Clinical Setting

tetano

Editor, Senior Moderator
J Gen Intern Med


. 2022 Mar 17.
doi: 10.1007/s11606-022-07448-x. Online ahead of print.
Evaluation of Five Commercial SARS-CoV-2 Antigen Tests in a Clinical Setting


Tamara Seitz[SUP] 1 [/SUP], Benno Lickefett[SUP] 2 [/SUP], Marianna Traugott[SUP] 2 [/SUP], Erich Pawelka[SUP] 2 [/SUP], Mario Karolyi[SUP] 2 [/SUP], Sebastian Baumgartner[SUP] 2 [/SUP], Sonja Jansen-Skoupy[SUP] 3 4 [/SUP], Johanna Atamaniuk[SUP] 3 4 [/SUP], Robert Fritsche-Polanz[SUP] 3 4 [/SUP], Johannes Asenbaum[SUP] 3 4 [/SUP], Christoph Wenisch[SUP] 2 [/SUP], Manuela Födinger[SUP] 3 4 [/SUP], Alexander Zoufaly[SUP] 2 4 [/SUP]



Affiliations

Abstract

Background: Point-of-care antigen tests (AgTs) for the detection of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) enable the rapid testing of infected individuals and are easy-to-use. However, there are few studies evaluating their clinical use.
Objective: The present study aimed to evaluate and compare the clinical performance characteristics of various commercial SARS-CoV-2 AgTs.
Design: The sensitivity of five AgTs, comprising four rapid antigen tests (RAT; AMP Rapid Test SARS-CoV-2 Ag, NADAL COVID-19 Antigen Rapid Test, CLINITEST Rapid COVID-19 Antigen Test, and Roche SARS-CoV-2 Rapid Antigen Test) and one sandwich chemiluminescence immunoassay (CLIA; LIAISON SARS-CoV-2 Assay), were evaluated in 300 nasopharyngeal (NP) swabs. Reverse transcriptase (RT) polymerase chain reaction (PCR) was used as a reference method.
Participants: NP swabs were collected from patients admitted to hospital due to COVID-19.
Key results: Sensitivities of the AgTs ranged from 64.9 to 91.7% for samples with RT-PCR cycle threshold (Ct) values lower than 30 and were 100% for cycle threshold (Ct) values lower than 20. The highest sensitivity was observed for CLINITEST Rapid COVID-19 Antigen Test, and Roche SARS-CoV-2 rapid antigen test. Multivariate analysis using time from symptom onset and the Ct value for AgT sensitivity showed an inverse correlation. Further, the female sex was an independent factor of lower RAT sensitivity.
Conclusions: Antigen tests from NP swab samples show high sensitivity in patients with a Ct value < 20. The best clinical sensitivity can be obtained using AgTs within the first 6 days after symptom onset.

Keywords: COVID-19; RAT; SARS-CoV-2; pandemic; rapid antigen testing.
 
Back
Top Bottom